Subsequent research has indicated that anti-PCSK9 treatment may hold the potential to mitigate liver fibrosis by modulating the AMPK/mTOR/ULK1 signaling pathway, thus reducing hypoxia-induced autophagy in hepatocytes [53]. The gene discussed is PCSK9; the disease is Hepatic fibrosis.